This grant has ended and is part of our past portfolio of work.
Principal Investigator(s):
Muktar Aliyu, M.D., M.P.H., Dr.P.H.
Michael DeBaun, M.D., M.P.H.
Hydroxyurea for Stroke Prevention in Children with Sickle Cell Disease in Sub-Saharan Africa
Our goals are: 1) to assess the efficacy of moderate dose HU therapy for secondary stroke prevention when compared to low dose HU therapy among children with SCA; and 2) to determine whether moderate HU therapy decreases the rate of all-cause hospitalizations when compared to low dose HU therapy.